logo
Plus   Neg
Share
Email

Novartis: Cosentyx Shows Efficacy At 12 Weeks Of MAXIMISE Trial

Novartis (NVS) said the ongoing 52-week Phase IIIb MAXIMISE trial evaluating Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis met both its primary and key secondary endpoint with 63.1% of Cosentyx 300 mg and 66.3% of Cosentyx 150 mg patients achieving ASAS20 at Week 12 (versus 31.3% for placebo) respectively. The safety results were consistent with previous clinical trials.

The data from the trial provide an extra evidence to support Cosentyx as a treatment across multiple psoriatic disease manifestations.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple chief executive officer Tim Cook condemned the killing of an unarmed black man, George Floyd, and called for the creation of a "better, more just world for everyone," according to reports citing a memo to employees. Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining.
Follow RTT